Discuss this signal with compliance peers, get the weekly digest, and never miss an enforcement deadline that affects your products.
The European Chemicals Agency (ECHA) is conducting scientific assessment of a comprehensive PFAS restriction REACH proposal that could ban over 10,000 per- and polyfluoroalkyl substances across the EU. The universal restriction proposal, submitted by five Member State authorities in January 2023, represents the broadest class-based restriction ever proposed under REACH regulation.
The ECHA PFAS proposal marks a fundamental shift from REACH's traditional substance-specific approach to a class-based restriction covering all per- and polyfluoroalkyl substances. German, Dutch, Swedish, Danish and Norwegian Member State Competent Authorities submitted the proposal to address what they characterise as shared characteristics of PFAS including persistence, bioaccumulation, and environmental mobility.
PFAS substances are embedded across industrial supply chains in textiles, food contact materials, electronics, firefighting foams, medical devices, and automotive components. The proposed restriction scope encompasses manufacture, placing on the market, and use of PFAS in substances, mixtures, and articles.
ECHA published an updated restriction proposal on 20 August 2025 following evaluation of over 5,600 public comments received during the six-month consultation period. The updated proposal expands coverage to 23 sectors, adding eight new use categories to the original 15 sectors assessed.
ECHA announced on 27 August 2025 that its Risk Assessment Committee (RAC) and Committee for Socio-Economic Analysis (SEAC) will complete their scientific evaluation by the end of 2026. The agency stated that including sector-specific evaluation of the eight additional sectors would require significant time beyond 2026 to finalise opinions.
The proposal operates under Article 68 of REACH Regulation (EC) No 1907/2006, which permits restrictions on manufacture, placing on the market, and use of substances that pose unacceptable risk to human health or the environment. The restriction would be implemented through addition to REACH Annex XVII.
The PFAS definition covers any substance containing at least one fully fluorinated methyl (CF3-) or methylene (-CF2-) carbon atom without hydrogen, chlorine, bromine, or iodine attached. This structural definition captures fluoropolymers, fluorinated surfactants, and fluorinated intermediates across chemical families.
Unlike traditional REACH restrictions targeting specific substances with CAS numbers, this proposal establishes a grouping approach based on molecular structure. The approach aims to prevent regrettable substitution within the PFAS class while addressing analytical challenges in identifying individual PFAS substances.
The restriction affects multiple industrial sectors with varying dependency on PFAS functionality. High-impact sectors include aerospace, automotive, electronics, medical devices, and renewable energy where PFAS provide critical performance characteristics including chemical resistance, thermal stability, and electrical insulation.
Textile manufacturers face restrictions on fluorinated water-repellent treatments used in outdoor clothing, protective equipment, and technical textiles. Food contact material producers must address PFAS-based barrier coatings in packaging applications. Electronics manufacturers confront restrictions on PFAS-containing semiconductors, printed circuit boards, and cable insulation.
The proposal includes time-limited derogations for specific uses where alternatives are not technically feasible. However, ECHA committees are recommending removal or significant reduction of many proposed derogations based on their assessment of technical alternatives and substitution timelines.
Manufacturers and importers must identify PFAS substances in their supply chains using the structural definition rather than relying on CAS number lists. This requires enhanced analytical capabilities and supplier engagement to detect PFAS presence in complex mixtures and articles.
Companies must assess whether their uses qualify for proposed derogations and prepare technical justification for essential use claims. The proposal establishes criteria for essential use including societal benefit, lack of alternatives, and minimised emissions throughout the lifecycle.
Downstream users must evaluate substitution options and timeline feasibility for PFAS-dependent processes. The restriction includes notification requirements for certain exempted uses and mandatory emission reporting for industrial applications.
ECHA's RAC and SEAC committees will deliver final opinions by December 2026. The European Commission will then prepare a legislative proposal based on committee recommendations, with adoption expected in 2027-2028.
Implementation timelines vary by sector and use category. The proposal includes transition periods ranging from 18 months for certain consumer applications to 12 years for specialised industrial uses. Firefighting foam applications face a 5-year transition period with interim restrictions on training use.
Enforcement will occur through Member State market surveillance authorities using existing REACH compliance mechanisms. The structural definition approach may require development of new analytical methods for enforcement laboratories to detect PFAS presence across diverse product categories.
Norway participates as a submitting authority despite being outside the EU, reflecting EEA-wide application of REACH restrictions. The proposal will apply across all EU Member States and EEA countries upon adoption.
Several Member States have implemented national PFAS restrictions that may be superseded by the EU-wide measure. Denmark restricted PFAS in food contact materials in 2020, while Germany has proposed restrictions on PFAS in firefighting foams. These national measures provide precedent for enforcement approaches.
The restriction scope excludes pharmaceutical active ingredients and plant protection products, which remain subject to sector-specific EU legislation. Medical device applications face sector-specific assessment under the Medical Device Regulation framework.
Conduct comprehensive PFAS inventory across all product lines using the structural definition criteria. Engage analytical laboratories capable of broad-spectrum PFAS detection rather than targeted analysis for specific substances. Many companies discover unexpected PFAS presence in imported components or raw materials.
Map supply chain dependencies and identify critical PFAS applications where substitution may require significant lead time. Prioritise assessment of high-volume products and applications with shortest proposed transition periods. Engage suppliers early to understand PFAS content and availability of alternatives.
Evaluate qualification for proposed derogations and prepare technical documentation supporting essential use claims. Monitor ECHA committee discussions and stakeholder submissions to understand evolving derogation scope. The committees are recommending narrower derogations than originally proposed.
Develop substitution roadmaps with realistic timelines for PFAS phase-out. Consider performance requirements, regulatory approval timelines for alternatives, and customer acceptance criteria. Some alternatives may require significant reformulation or process changes.
Establish monitoring system for regulatory developments including committee meeting outcomes, stakeholder consultation responses, and Commission legislative drafting. The final restriction scope and timelines may differ significantly from the original proposal based on committee recommendations.